shock! How much can patients buy a box of giritinib in 2024?

Gilitinib (Gilteritinib) is a FLT3/AXL kinase inhibitor used to treat U.S. Food and Drug Administration (FDA) Accurate tests detect FLT3 mutations in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The brand name Xospata is administered orally once daily.

The efficacy of geritinib was studied in the ADMIRAL trial, which followed 138 patients with relapsed or refractory acute myeloid leukemia with confirmed FLT3 mutations. 21% of patients achieved complete or complete remission with partial hematologic recovery with treatment. Of the 106 patients who required red blood cell or platelet transfusions at the start of giritinib treatment, 31% were transfusion-free for at least 56 days. The most common side effects reported in clinical trials were myalgia/arthralgia, elevated transaminases, fatigue/malaise, pyrexia, non-infectious diarrhea, dyspnea, edema, rash, pneumonia, nausea, stomatitis, cough, headache, hypotension, dizziness, and vomiting.

The original drug of giritinib has been launched in China, but it has not yet been included in the medical insurance. The price of each box of 40mg*42 tablets may be more than 20,000 yuan, and the price of the Hong Kong version of the original drug is about 90,000 yuan per box. The price of the European version of the original drug, 40mg*84 tablets, per box listed overseas is around RMB 210,000 (the price may fluctuate due to exchange rates), which is very expensive. Generic drugs of giritinib are currently produced and sold overseas, and their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 40mg*84 tablets per box produced by a Laos pharmaceutical factory is more than 4,000 yuan (the price may fluctuate due to the exchange rate).